

CLAIM LISTING

1-20. (Canceled).

21. (Currently amended) A chimeric anti-CD20 antibody having a variable light chain comprising the amino acid sequence ~~encoded by the nucleic acid sequence in shown in SEQ ID NO: 4~~ and a variable heavy chain ~~encoded by the nucleic acid sequence in SEQ ID NO:5 comprising the amino acid sequence shown in SEQ ID NO: 6~~

22. (Currently amended) ~~An A chimeric anti-CD20 variable light chain comprising the amino acid sequence encoded by the nucleic acid sequence in SEQ ID NO:3 shown in SEQ ID NO: 4.~~

23. (Currently amended) ~~An A chimeric anti-CD20 variable heavy chain comprising the amino acid sequence encoded by the nucleic acid sequence in SEQ ID NO:5 shown in SEQ ID NO: 6.~~

24. (Currently amended) A chimeric anti-CD20 antibody having a variable light chain ~~comprising the amino acid sequence encoded by the nucleic acid sequence in SEQ ID NO:3 shown in SEQ ID NO: 4.~~

25. (Currently amended) A chimeric anti-CD20 antibody having a variable heavy chain ~~comprising the amino acid sequence encoded by the nucleic acid sequence in SEQ ID NO:5 shown in SEQ ID NO: 6.~~

26. (Previously presented) The chimeric anti-CD20 antibody of Claim 21 which is an IgG1.

27. (Previously presented) The chimeric anti-CD20 antibody of Claim 24 which is an IgG1.

28. (Previously presented) The chimeric anti-CD20 antibody of Claim 25 which is an IgG1.
29. (Previously presented) The chimeric anti-CD20 antibody of Claim 21 which comprises a radiolabel.
30. (Currently amended) The chimeric anti-CD20 antibody of Claim 29 wherein said the radiolabel is selected from the group consisting of yttrium-90 (90), indium-111, (131) and iodine-131 (131).
31. (Currently amended) The chimeric anti-CD20 antibody of Claim 21 wherein said the radiolabel is attached to the antibody via a chelate chelator.
32. (Currently amended) The chimeric anti-CD20 antibody of the Claim 31 wherein the chelate chelator is MX-DTPA.
33. (Previously presented) The chimeric anti-CD20 antibody of Claim 24 which comprises a radiolabel.
34. (Currently amended) The chimeric anti-CD20 antibody of Claim 24 wherein said the radiolabel is selected from the group consisting of yttrium-90 (90), indium-111, (131) and iodine-131 (131).
35. (Currently amended) The chimeric anti-CD20 antibody of Claim 24 wherein said the radiolabel is attached to the antibody via a chelate chelator.
36. (Currently amended) The chimeric anti-CD20 antibody of Claim 24 wherein the chelate chelator is MX-DTPA.

37. (Previously presented) The chimeric anti-CD20 antibody of Claim 25 which comprises a radiolabel.
38. (Currently amended) The chimeric anti-CD20 antibody of Claim 25 wherein said the radiolabel is selected from the group consisting of yttrium-90 (90), indium-111, (131) and iodine-131 (131).
39. (Currently amended) The chimeric anti-CD20 antibody of Claim 25 wherein said the radiolabel is attached to the antibody via a chelate chelator.
40. (Currently amended) The chimeric anti-CD20 antibody of the Claim 25 wherein the chelate chelator is MX-DTPA.
41. (Previously presented) A pharmaceutical composition comprising a chimeric anti-CD20 antibody according to Claim 21 and a pharmaceutically acceptable carrier.
42. (Previously presented) An imaging composition comprising a chimeric anti-CD20 antibody according to Claim 21 and an acceptable carrier.
43. (Previously presented) The pharmaceutical composition of Claim 41 which comprises a radiolabel.
44. (Previously presented) The imaging composition of Claim 42 which comprises a radiolabel.
45. (Currently amended) The pharmaceutical composition of Claim 43 wherein said the radiolabel is yttrium-90 (90) or iodine-131 (131).

46. (Currently amended) The imaging composition of Claim 44 wherein said the radiolabel is indium-111 (111).
47. (Previously presented) The pharmaceutical composition of Claim 41 which is suitable for parenteral administration.
48. (Currently amended) The pharmaceutical composition of Claim 47 wherein the parenteral administration is selected from the group consisting of subcutaneous, intravenous, intramuscular, vaginal, intraperitoneal and subcutaneous administration.
49. (Previously presented) The imaging composition of Claim 42 which is suitable for parenteral administration.
50. (Currently amended) The imaging composition of Claim 49 wherein the parenteral administration is selected from the group consisting of subcutaneous, intravenous, intramuscular, vaginal, intraperitoneal and subcutaneous administration.
51. (Currently amended) The pharmaceutical composition of Claim 41 which an effective dosage dose ranging from about 0.01 to 30 mg/kg body weight upon administration to a patient.
52. (Currently amended) The pharmaceutical composition of Claim 51 wherein said dosage the dose ranges from about 0.01 to about 25 mg/kg body weight.
53. (Currently amended) The pharmaceutical composition of Claim 51 wherein said dosage the dose ranges from about 0.4 mg to about 20.0 20 mg/kg body weight.

54. (Currently amended) The imaging composition of Claim 42 which ~~delivers~~ is formulated to deliver a dosage dose of radiation ranging from about 1 to 10mCi upon administration to a patient.
55. (Currently amended) The imaging composition of Claim 54 wherein the radiolabel is indium-111 (111).
56. (Currently amended) The imaging composition of Claim 55 wherein the ~~dosage dose~~ of radiation is about 5 mCi.
57. (Currently amended) The pharmaceutical composition of Claim 43 which is non-myeloablative when administered to a patient.
58. (Currently amended) An isolated anti-CD20 antibody comprising a variable light chain comprising the amino acid sequence encoded by the nucleic acid sequence in SEQ ID NO:3 shown in SEQ ID NO: 4.
59. (Currently amended) The anti-CD20 antibody of Claim 58 wherein said the antibody is murine.
60. (Previously presented) The anti-CD20 antibody of Claim 59 further comprising a radiolabel.
61. (Currently amended) The anti-CD20 antibody of Claim 60 wherein said the radiolabel is selected from the group consisting of yttrium-90 (90), indium-111, (111) and iodine-131 (131).
62. (Currently amended) The anti-CD20 antibody of Claim 61 wherein said the radiolabel is yttrium-90 (90).

63. (Currently amended) An isolated anti-CD20 antibody comprising a variable heavy chain comprising the amino acid sequence ~~encoded by the nucleic acid sequence in SEQ ID NO:5~~ shown in SEQ ID NO: 6.
64. (Currently amended) The anti-CD20 antibody of Claim 63 wherein ~~said~~ the antibody is murine.
65. (Previously presented) The anti-CD20 antibody of Claim 63 further comprising a radiolabel.
66. (Currently amended) The anti-CD20 antibody of Claim 64 wherein ~~said~~ the radiolabel is selected from the group consisting of yttrium-90 (90), indium-111, (111) and iodine-131 (131).
67. (Currently amended) The anti-CD20 antibody of Claim 65 wherein ~~said~~ the radiolabel is yttrium-90 (90).